Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

The search for an HIV prevention vaccine news

Show

From To
Despite Uptick, Black and Latinx People Have Relatively Low Participation in HIV Vaccine Trials

Black and Latinx people historically have not willfully participated in clinical trials in high numbers. Medical mistrust of research and health care institutions has long been a problem for conducting biomedical research. So what's causing the racial disparities in research participation, and what are researchers doing about it?

Published
14 May 2019
From
The Body Pro
NIH Awards Will Advance Development of Vaccines for Sexually Transmitted Infections

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.

Published
10 May 2019
From
National Institute of Allergy and Infectious Diseases
Scientists Identify Factors That Make People Naturally Resistant to HIV

Studying key points on the HIV virus that are weak to immune system attacks could lead to new treatments or HIV vaccines.

Published
07 May 2019
From
Smithsonian
HIV vaccine science in Africa, for Africa

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

Published
03 May 2019
From
IAVI Report
HIV antibody VRC01LS safe prevention strategy for infants

Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

Published
12 March 2019
From
Healio
CROI 2019: Thailand’s strides spanned HIV treatment, prevention and research

he first HIV vaccine trials to yield signs of hope happened here. Thailand was also the first Asian country to eliminate mother-to-child transmission of HIV. Now, Thailand has achieved the first part of UNAIDS’ 90-90-90 targets: 98 percent of people infected with HIV know their status.

Published
06 March 2019
From
Science Speaks
Mind the Gap: The Burden of HIV Among Racial and Ethnic Minority Groups and Their Participation in Preventive HIV Vaccine Clinical Trials

An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports.

Published
16 February 2019
From
HIV Vaccine Trials Network
Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

Published
30 January 2019
From
Positively Aware
Scientists achieve the first proof of concept for an HIV broadly neutralising antibody vaccine in monkeys

In a step forward in the search for an HIV vaccine, Professor Denis Burton and colleagues from the Scripps Institute in La Jolla, California have manufactured an

Published
02 January 2019
By
Gus Cairns
HIV vaccine protects non-human primates from infection

The new study shows that rhesus macaque monkeys can be prompted to produce neutralizing antibodies against one strain of HIV that resembles the resilient viral form that most commonly infects people, called a Tier 2 virus. The research also provides the first-ever estimate of vaccine-induced neutralizing antibody levels needed to protect against HIV.

Published
17 December 2018
From
Scripps Institute

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.